Vol.7 No.4 – 5: Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes
By: Rania A. El-Leithy1, Aly F. Mohamed2, Asmaa A. EL-refaay1, Mohamed M. Omran1, * 1Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt 2Former Head of R&D Sector, The Holding Company for Production of Vaccines, Sera and Drugs (VACSERA), Giza, Egypt Abstract Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here […]